2.34
14.15%
-0.38
전일 마감가:
$2.72
열려 있는:
$2.66
하루 거래량:
150.54K
Relative Volume:
3.97
시가총액:
$32.79M
수익:
$52.16M
순이익/손실:
$-48.60M
주가수익비율:
-2.5714
EPS:
-0.91
순현금흐름:
$-77.48M
1주 성능:
-25.64%
1개월 성능:
-41.48%
6개월 성능:
-72.76%
1년 성능:
-49.23%
Hookipa Pharma Inc Stock (HOOK) Company Profile
명칭
Hookipa Pharma Inc
전화
0114318906360
주소
350 FIFTH AVENUE, 72ND FLOOR, SUITE 7240, NEW YORK, NY
HOOK을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
HOOK | 2.335 | 32.79M | 52.16M | -48.60M | -77.48M | -0.91 |
VRTX | 448.93 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 746.47 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 597.75 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 246.43 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 108.14 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Hookipa Pharma Inc Stock (HOOK) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2022-12-02 | 다운그레이드 | BofA Securities | Buy → Underperform |
2021-11-12 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2021-04-08 | 개시 | Morgan Stanley | Overweight |
2020-11-03 | 개시 | Truist | Buy |
2020-10-26 | 개시 | JMP Securities | Mkt Outperform |
2020-10-19 | 재개 | H.C. Wainwright | Buy |
2019-09-27 | 개시 | H.C. Wainwright | Buy |
2019-05-13 | 개시 | BofA/Merrill | Buy |
2019-05-13 | 개시 | RBC Capital Mkts | Outperform |
모두보기
Hookipa Pharma Inc 주식(HOOK)의 최신 뉴스
Hookipa Pharma stock hits 52-week low at $2.62 amid market challenges - Investing.com
Companies Like HOOKIPA Pharma (NASDAQ:HOOK) Could Be Quite Risky - Simply Wall St
HOOKIPA Pharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
RBC Capital Mkts reiterated coverage on HOOKIPA Pharma with a new price target - Quantisnow
HOOKIPA Pharma stock target lowered, maintains outlook on strategic direction - Investing.com UK
HOOKIPA Pharma Inc (HOOK) Quarterly 10-Q Report - Quartzy
Hookipa Pharma stock hits 52-week low at $3.4 amid market challenges - Investing.com Australia
Hookipa Pharma Reports Q3 Earnings Amid Strategic Changes - TipRanks
HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates - The Bakersfield Californian
HOOKIPA Pharma's Eseba-vec Highlighted in SITC Late-Breaker - Quantisnow
HOOKIPA Pharma's SWOT analysis: stock's potential in immunotherapy market - Investing.com
HOOKIPA Pharma's SWOT analysis: stock's potential in immunotherapy market By Investing.com - Investing.com UK
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024 - Quantisnow
HOOKIPA commences HPV16+ cancer adjuvant care trial - Investing.com India
HOOKIPA commences HPV16+ cancer adjuvant care trial By Investing.com - Investing.com Nigeria
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer - The Manila Times
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator - The Bakersfield Californian
Hookipa Pharma stock hits 52-week low at $3.91 amid market challenges By Investing.com - Investing.com South Africa
Hookipa Pharma stock hits 52-week low at $3.91 amid market challenges - Investing.com
Hookipa Pharma stock hits 52-week low at $4.06 amid market challenges - Investing.com
HOOKIPA Pharma's SWOT analysis: stock's potential in cancer immunotherapy - Investing.com
HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) 26% Dip In Price Shows Sentiment Is Matching Revenues - Simply Wall St
HOOKIPA presents KRAS cancer treatment data By Investing.com - Investing.com South Africa
HOOKIPA presents KRAS cancer treatment data - Investing.com India
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset - Marketscreener.com
Squamous Cell Carcinoma Clinical Trial Pipeline Insights: 75+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space | DelveInsight - GlobeNewswire Inc.
Kaskela Law LLC Announces Shareholder Investigation of HOOKIPA Pharma Inc. (NASDAQ: HOOK) and Encourages Investors to Contact the Firm | FinancialContent Business Page - Financial Content
How To Trade (HOOK) - Stock Traders Daily
Wall Street Analysts Think HOOKIPA Pharma (HOOK) Could Surge 622.75%: Read This Before Placing a Bet - MSN
HOOKIPA appoints new Non-Executive Chair as two members exit - Investing.com India
HOOKIPA appoints new Non-Executive Chair as two members exit By Investing.com - Investing.com South Africa
HOOKIPA Pharma Announces Board of Directors Changes - citybiz
Hookipa Pharma Announces Board Restructuring and Appointments - TipRanks
HOOKIPA Pharma to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Hookipa Pharma Inc (NASDAQ:HOOK) Short Interest Update - MarketBeat
Will HOOKIPA Pharma Inc. (HOOK) Report Negative Q2 Earnings? What You Should Know - MSN
HOOK (HOOKIPA Pharma) 3-Year FCF Growth Rate : 25.90% (As of Jun. 2024) - GuruFocus.com
HOOK (HOOKIPA Pharma) 3-Year Revenue Growth Rate : -34.30% (As of Jun. 2024) - GuruFocus.com
The Market Doesn't Like What It Sees From HOOKIPA Pharma Inc.'s (NASDAQ:HOOK) Revenues Yet As Shares Tumble 29% - Simply Wall St
HOOKIPA Pharma Second Quarter 2024 Earnings: Revenues Miss Expectations - Yahoo Finance
HOOK Stock Earnings: HOOKIPA Pharma Misses EPS, Misses Revenue for Q2 2024 - InvestorPlace
The Globe and Mail - The Globe and Mail
HOOKHOOKIPA Pharma Inc. Latest Stock News & Market Updates - StockTitan
SEC Form 10-Q filed by HOOKIPA Pharma Inc. - Quantisnow
HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights - ForexTV.com
Hookipa Pharma Inc (HOOK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):